251 related articles for article (PubMed ID: 15043529)
1. Activated protein C resistance in anterior ischaemic optic neuropathy.
Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
[TBL] [Abstract][Full Text] [Related]
2. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
3. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
Rehak M; Rehak J; Müller M; Faude S; Faude F; Siegemund A; Krcova V; Slavik L; Hasenclever D; Scholz M; Wiedemann P
Thromb Haemost; 2008 May; 99(5):925-9. PubMed ID: 18449423
[TBL] [Abstract][Full Text] [Related]
7. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
Torres JD; Cardona H; Alvarez L; Cardona-Maya W; Castañeda SA; Quintero-Rivera F; Cadavid A; Bedoya G; Tobón L
Am J Hematol; 2006 Dec; 81(12):933-7. PubMed ID: 16917913
[TBL] [Abstract][Full Text] [Related]
8. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Dahlbck B
J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
[TBL] [Abstract][Full Text] [Related]
9. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy.
Salomon O; Huna-Baron R; Kurtz S; Steinberg DM; Moisseiev J; Rosenberg N; Yassur I; Vidne O; Zivelin A; Gitel S; Davidson J; Ravid B; Seligsohn U
Ophthalmology; 1999 Apr; 106(4):739-42. PubMed ID: 10201595
[TBL] [Abstract][Full Text] [Related]
10. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Kabukcu S; Keskin N; Keskin A; Atalay E
Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
[TBL] [Abstract][Full Text] [Related]
11. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Strandberg K; Svensson PJ; Ohlin AK
Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
[TBL] [Abstract][Full Text] [Related]
13. [Factor V Leiden and the Slovak population].
Hudecek J; Dobrotová M; Hybenová J; Ivanková J; Melus V; Pullmann R; Kubisz P
Vnitr Lek; 2003 Nov; 49(11):845-50. PubMed ID: 14689680
[TBL] [Abstract][Full Text] [Related]
14. Factor V Leiden mutation in one family of Chinese origin.
Wu J; Gu J; Xu J; Wang J; Sun Z; Smirnov MD; Morrissey JH; Esmon N
Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458
[TBL] [Abstract][Full Text] [Related]
15. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
[TBL] [Abstract][Full Text] [Related]
16. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Tosetto A; Castaman G; Cappellari A; Rodeghiero F
Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
[TBL] [Abstract][Full Text] [Related]
17. Coagulation factor V and thrombophilia: background and mechanisms.
Segers K; Dahlbäck B; Nicolaes GA
Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Schöni R; Quehenberger P; Wu JR; Wilmer M
Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
[TBL] [Abstract][Full Text] [Related]
20. [Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age].
Kuhli-Hattenbach C; Scharrer I; Lüchtenberg M; Hattenbach LO
Klin Monbl Augenheilkd; 2008 Dec; 225(12):1065-9. PubMed ID: 19085787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
